Research Alliance II (Research Alliance II) Cash, Cash Equivalents, Marketable Securities : $0.40 Mil (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Research Alliance II Cash, Cash Equivalents, Marketable Securities?

Research Alliance II's quarterly cash, cash equivalents, marketable securities declined from Mar. 2022 ($0.76 Mil) to Jun. 2022 ($0.62 Mil) but then stayed the same from Jun. 2022 ($0.62 Mil) to Sep. 2022 ($0.40 Mil).

Research Alliance II's annual cash, cash equivalents, marketable securities increased from . 20 ($0.00 Mil) to Dec. 2020 ($0.22 Mil) and increased from Dec. 2020 ($0.22 Mil) to Dec. 2021 ($1.05 Mil).

Research Alliance II Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Research Alliance II's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Research Alliance II Cash, Cash Equivalents, Marketable Securities Chart

Research Alliance II Annual Data

Trend

Dec20

Dec21

Cash, Cash Equivalents, Marketable Securities

0.22

1.05

Research Alliance II Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial			1.15	1.05	0.76	0.62	0.40

Research Alliance II Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Research Alliance II (NAS:RACB) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Research Alliance II Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Research Alliance II's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Research Alliance II (Research Alliance II) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Research Alliance Corp II (NAS:RACB) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

3172 North Rainbow Boulevard, Suite 1278, Las Vegas, NV, USA, 89108

Website

https://www.researchalliancecorp.com

Research Alliance Corp II is a blank check company.

Executives

Saba Capital Management, L.p.	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Boaz Weinstein	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Peter Kolchinsky	director, officer: Chief Executive Officer	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Stephen J Hoffman	director	C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301
Thomas Leggett	director	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Matthew Hammond	director, officer: Chief Investment Officer	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Research Alliance Holdings Ii Llc	10 percent owner	200 BERKELEY STREET 18TH FLOOR, BOSTON MA 02116
Theresa Cameron	director, 10 percent owner, officer: Chief Financial Officer	C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116
Clive Patience	director	C/O RESEARCH ALLIANCE CORP. II, 3172 NORTH RAINBOW BLVD. SUITE 1278, LAS VEGAS NV 89108

Research Alliance II (Research Alliance II) Headlines

From GuruFocus

POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility

By Business Wire Business Wire • 04-28-2021

Research Alliance Corp. II Will Redeem Public Shares

By Business Wire Business Wire • 11-28-2022